Forbes contributors publish independent expert analyses and insights. I focus on new drugs and innovations in medical devices. Last week, the FDA approved XCOPRI (cenobamate tablets) to treat ...

SK Life Science has announced the availability of Xcopri (cenobamate) tablets for the treatment of partial-onset seizures in adults.  SK Life Science has announced the availability of Xcopri ...

POTIGA (ezogabine) 50mg, 200mg, 300mg, 400mg tablets by GlaxoSmithKline The FDA has approved Potiga (ezogabine tablets; Valeant and GlaxoSmithKline) as adjunct treatment for partial-onset seizures in ...

Since 1983, eight new AEDs have been introduced (see Table 2 below). Sadly, a recent VA study of more than 21,000 subjects aged 65 years and older revealed that 80% were being treated with ...

Zug, Switzerland, 12 May 2020 - Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS disorders, today confirms that SK ...

SILVER SPRING, Md., Nov. 21, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration today approved XCOPRI (cenobamate tablets) to treat partial-onset seizures in adults. "XCOPRI is a new option to ...

New findings from a phase 3 clinical trial suggest an additional therapeutic option may be coming down the pike. Researchers performed a randomized, double-blind, placebo-controlled study in the ...

Novel, anti-epilepsy treatment Exalief ® will soon be available in Russia. (Exalief is also marketed under the trade name Zebinix in Europe). Once-daily eslicarbazepine acetate is indicated in Europe ...

Gabapentin is commonly prescribed for nerve pain, seizures, and restless legs syndrome, but it also carries certain risks.

Moving forward The CDC reports that one in 100 U.S. adults has active epilepsy, and studies suggest that one third of these are not receiving adequate treatment or care. 30 Although this recent report ...